Japanese biotech pays Albireo $135M for local liver disease drug rights

Japanese biotech Jadeite Medicines is paying Boston-based Albireo Pharma Inc. up to $135 million for Japanese rights to Bylvay, the company’s recently approved drug for rare liver diseases.